The Agency is holding a two-day workshop on 27-28 September 2012. It will focus on outcome measures for Cystic Fibrosis (CF) lung disease and exocrine pancreatic insufficiency, gathering experts in the field of CF together with regulators, pharmaceutical industry, and patient representatives. Registration by invitation only. Registration open until 31/07/2012. Places limited.
Go to Source

This entry was posted on Monday, July 2nd, 2012 at 11:30 am and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.